中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.025 seconds)

    Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
    1.
    发明授权
    Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells 有权

    公开(公告)号：US10421961B2

    公开(公告)日：2019-09-24

    申请号：US13377558

    申请日：2010-06-10

    Applicant: Chaya Brodie ,  Shimon Slavin

    Inventor： Chaya Brodie ,  Shimon Slavin

    IPC: C12N15/113 ,  C12N5/0793 ,  A61K31/7105

    Abstract: Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.

    METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME
    2.
    发明申请
    METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME 有权
    产生含有寡糖的小鼠和细胞群体的方法

    公开(公告)号：US20130149288A1

    公开(公告)日：2013-06-13

    申请号：US13817535

    申请日：2011-08-14

    Applicant: Shimon Slavin ,  Chaya Brodie

    Inventor： Shimon Slavin ,  Chaya Brodie

    IPC: C12N5/079

    CPC classification number: C12N5/0622 ,  A61K35/12 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/30 ,  C12N2330/10 ,  C12N2500/25 ,  C12N2501/39 ,  C12N2501/65 ,  C12N2506/025 ,  C12N2506/1353 ,  C12N2506/1384 ,  C12N2506/1392

    Abstract: A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.

    Abstract translation: 公开了一种产生可用于治疗受试者脑部疾病的细胞群的方法。 所述方法包括使间充质干细胞（MSC）与至少一种外源miRNA接触，所述外源miRNA具有与选自SEQ ID NO：15-19和27-35的序列至少90％相同的核酸序列，从而产生 细胞群和/或产生神经营养因子，其可以向受损组织或局部驻留的干细胞提供重要信号。 通过miR分化的MSC也可以分泌miR并将其递送至相邻细胞，并因此向相邻内源性正常或恶性细胞提供重要信号。

    SYNTHETIC SPHINGOLIPID ANALOGS
    3.
    发明申请
    SYNTHETIC SPHINGOLIPID ANALOGS 审中-公开
    合成弹性体类似物

    公开(公告)号：US20100311841A1

    公开(公告)日：2010-12-09

    申请号：US12742036

    申请日：2008-11-06

    Applicant: Arie Dagan ,  Shimon Gatt ,  Shimon Slavin

    Inventor： Arie Dagan ,  Shimon Gatt ,  Shimon Slavin

    IPC: A61K31/135 ,  C07C213/00

    CPC classification number: C07C323/32 ,  C07C381/12

    Abstract: Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.

    Abstract translation: 提供了基于合成鞘脂类似物的治疗化合物，特别是烷基硫代苯基取代的神经酰胺类似物，其适于治疗退行性，感染性和其它疾病。

    Methods of treatment of hematopoietic disorders
    4.
    发明授权
    Methods of treatment of hematopoietic disorders 有权
    造血障碍治疗方法

    公开(公告)号：US07347999B2

    公开(公告)日：2008-03-25

    申请号：US10471048

    申请日：2002-03-05

    Applicant: Shimon Slavin ,  Olga Gurevitch ,  Basan Gowda S. Kurkalli ,  Tatyana Prigozhina

    Inventor： Shimon Slavin ,  Olga Gurevitch ,  Basan Gowda S. Kurkalli ,  Tatyana Prigozhina

    IPC: A61K35/32 ,  A61K35/28

    CPC classification number: A61K35/32 ,  A61K35/28 ,  A61K38/1875 ,  A61K2300/00

    Abstract: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.

    Abstract translation: 包含骨髓细胞（BMC）和去矿物质骨基质（DBM）和/或矿化骨基质（MBM）的组合物，任选地包括骨形态发生蛋白（BMP），特别是用于骨髓移植，进入骨髓腔或骨骼外 位点及其移植/植入方法。 本发明的组合物和方法能够恢复和/或增强源自移植的BMC的造血微环境的形成，并且可用于治疗造血障碍，例如干细胞和/或其产物的缺乏，导致 异常干细胞和/或产物，或恶性或非恶性起源的造血障碍。 本发明的组合物和方法也可用于诱导移植物穿刺，用于预防移植物抗宿主病。 最重要的是，本发明的组合物和方法可以用于治疗主要或二次影响支持和调节造血的基质微环境的疾病。 还提供了用于与DBM和/或MBM混合的用于移植到BMC的哺乳动物中的试剂盒。

    Non-myeloablative tolerogenic treatment
    6.
    发明授权
    Non-myeloablative tolerogenic treatment 有权
    非清髓性耐受性治疗

    公开(公告)号：US06428782B1

    公开(公告)日：2002-08-06

    申请号：US09222011

    申请日：1998-12-31

    Applicant: Shimon Slavin ,  Tatyana Prigozhina

    Inventor： Shimon Slavin ,  Tatyana Prigozhina

    IPC: A61K3800

    CPC classification number: A01K67/0271 ,  A61K35/17 ,  A61K35/28 ,  A61K39/001 ,  A61K2039/5158

    Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

    Abstract translation: 本发明的特征在于在宿主中诱导供体特异性耐受的方法。 本发明的耐受性治疗可以在移植供体来源的材料之前施用于宿主。 耐受性治疗涉及（1）以足以减少但不一定消除宿主哺乳动物功能性T淋巴细胞群体的非骨髓清除方案向宿主哺乳动物施用免疫抑制剂; （2）将来自非同基因供体的供体抗原输入宿主哺乳动物; （3）使用非清髓剂量的淋巴细胞毒性或耐受剂消除对输注的供体抗原的响应的宿主T淋巴细胞; 和（4）向宿主哺乳动物施用供体造血细胞。 用于宿主哺乳动物细胞治疗的供体淋巴细胞可以通过基本上类似于用于在移植前耐受宿主哺乳动物的那些方法来消耗宿主特异性免疫反应性。

Patent Agency Ranking